中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2010年
10期
1014-1017
,共4页
白旭东%岳蕴华%李伟孜%王红%陈丽
白旭東%嶽蘊華%李偉孜%王紅%陳麗
백욱동%악온화%리위자%왕홍%진려
急性脑卒中%同型半胱氨酸%白细胞介素-6%超敏C-反应蛋白
急性腦卒中%同型半胱氨痠%白細胞介素-6%超敏C-反應蛋白
급성뇌졸중%동형반광안산%백세포개소-6%초민C-반응단백
Acute stroke%Homocysteine acid%Interleukin-6%High sensitive c-reactive protein
目的 观察血清同型半胱氨酸(Hcy)及白细胞介素-6(IL-6)、超敏C-反应蛋白(hs-CRP)在不同病情程度急性脑卒中(AS)患者中的差异.方法 选择AS患者126例.按临床神经功能缺损程度评分标准进行病情程度及预后分组.分别测定发病后第3、14、28天血清Hcy、IL-6、hs-CRP浓度.选择同期健康体检者108名作为对照组.结果 ①AS组血清Hcy、IL-6和hs-CRP水平明显高于健康对照组[(58.24±9.86)、(17.12±4.23)μmol/L,(59.64±13.82)、(18.46±4.62)ng/L,(19.78±6.12)、(2.28±0.82)mg/L,t值分别为2.623、2.761、3.746,P均＜0.01];②发病第3天重、中、轻型AS组血清Hcy、IL-6、hs-CRP水平均高于健康对照组(P均＜0.01),且重型组、中型组高于轻型组(P均＜0.01);发病第14天重型组与中型组高于轻型组及健康对照组(P均＜0.01);发病第28天重型组高于中、轻型组及健康对照组(P均＜0.01).③发病第28天基本治愈组与显著进步组较无变化组的血清Hcy、IL-6、hs-CRP水平明显降低[(16.12±4.74)、(18.42±5.02)、(48.69±7.89)μmol/L,(19.52±5.67)、(20.74±6.13)、(51.26±11.66)ng/L,(3.21±1.36)、(3.24±2.51)、(8.86±1.32)mg/L,P均＜0.01].结论 血清Hcy、IL-6、hs-CRP是临床评价AS严重程度和预后的重要生物学指标.
目的 觀察血清同型半胱氨痠(Hcy)及白細胞介素-6(IL-6)、超敏C-反應蛋白(hs-CRP)在不同病情程度急性腦卒中(AS)患者中的差異.方法 選擇AS患者126例.按臨床神經功能缺損程度評分標準進行病情程度及預後分組.分彆測定髮病後第3、14、28天血清Hcy、IL-6、hs-CRP濃度.選擇同期健康體檢者108名作為對照組.結果 ①AS組血清Hcy、IL-6和hs-CRP水平明顯高于健康對照組[(58.24±9.86)、(17.12±4.23)μmol/L,(59.64±13.82)、(18.46±4.62)ng/L,(19.78±6.12)、(2.28±0.82)mg/L,t值分彆為2.623、2.761、3.746,P均＜0.01];②髮病第3天重、中、輕型AS組血清Hcy、IL-6、hs-CRP水平均高于健康對照組(P均＜0.01),且重型組、中型組高于輕型組(P均＜0.01);髮病第14天重型組與中型組高于輕型組及健康對照組(P均＜0.01);髮病第28天重型組高于中、輕型組及健康對照組(P均＜0.01).③髮病第28天基本治愈組與顯著進步組較無變化組的血清Hcy、IL-6、hs-CRP水平明顯降低[(16.12±4.74)、(18.42±5.02)、(48.69±7.89)μmol/L,(19.52±5.67)、(20.74±6.13)、(51.26±11.66)ng/L,(3.21±1.36)、(3.24±2.51)、(8.86±1.32)mg/L,P均＜0.01].結論 血清Hcy、IL-6、hs-CRP是臨床評價AS嚴重程度和預後的重要生物學指標.
목적 관찰혈청동형반광안산(Hcy)급백세포개소-6(IL-6)、초민C-반응단백(hs-CRP)재불동병정정도급성뇌졸중(AS)환자중적차이.방법 선택AS환자126례.안림상신경공능결손정도평분표준진행병정정도급예후분조.분별측정발병후제3、14、28천혈청Hcy、IL-6、hs-CRP농도.선택동기건강체검자108명작위대조조.결과 ①AS조혈청Hcy、IL-6화hs-CRP수평명현고우건강대조조[(58.24±9.86)、(17.12±4.23)μmol/L,(59.64±13.82)、(18.46±4.62)ng/L,(19.78±6.12)、(2.28±0.82)mg/L,t치분별위2.623、2.761、3.746,P균＜0.01];②발병제3천중、중、경형AS조혈청Hcy、IL-6、hs-CRP수평균고우건강대조조(P균＜0.01),차중형조、중형조고우경형조(P균＜0.01);발병제14천중형조여중형조고우경형조급건강대조조(P균＜0.01);발병제28천중형조고우중、경형조급건강대조조(P균＜0.01).③발병제28천기본치유조여현저진보조교무변화조적혈청Hcy、IL-6、hs-CRP수평명현강저[(16.12±4.74)、(18.42±5.02)、(48.69±7.89)μmol/L,(19.52±5.67)、(20.74±6.13)、(51.26±11.66)ng/L,(3.21±1.36)、(3.24±2.51)、(8.86±1.32)mg/L,P균＜0.01].결론 혈청Hcy、IL-6、hs-CRP시림상평개AS엄중정도화예후적중요생물학지표.
Objective To observe the changes of serum homocysteine acid ( Hcy),interleukin-6 (IL-6) and high sensitive C-reactive protein (hs-CRP) and elucidate the clinical significance in patients with acute stroke. Methods A total of 126 acute stroke patients were enrolled in the investigation. Based on the MESS,patients were divided into different groups according the severity and prognosis, and 108 physically healthy subjects were selected as controls. The concentration of serum Hcy, IL-6, and hs-CRP were determined in all cases after being attacked at day 3,day 14 and day 28 respectively. Results ①The levels of Hcy, IL-6, hs-CRP in patients with acute stroke were significantly higher than controls ( (58.24 ±9.86) μmol/L vs. ( 17.12 ±4.23) μ mol/L, (59.64 ±13.82) ng/L vs. (18.46 ±4.62) ng/L,(19.78 ±6.12) mg/L vs. (2.28 ±0.82) mg/L,all P＜0. 01 ). ②The levels of Hcy,IL-6, hs-CRP in patients with mild, moderate and severe acute stroke were significantly higher than controls (P ＜ 0.01 ) at 3 day after the onset; and the Hcy, IL-6, hs-CRP were also significantly lower in mild cases with acute stroke compared with moderate and severe cases (P ＜ 0. 01 ). At day 14 ,the moderate and severe patients had significantly higher levels of Hcy, IL-6, hs-CRP than mild cases and controls (P ＜ 0.01 ). At day 28 the severe patients had significantly higher levels of Hcy, IL-6, hs-CRP than mild and moderate cases and controls (P ＜ 0.01 ) ③At day 28, the levels of Hcy, IL-6, hs-CRP in basically recovered and remarkably improved cases were significantly lower than unrecovered cases [ ( 16.12 ± 4.74) μmol/L, ( 1 8.42 ± 5.02) μ mol/L vs. ( 48.69 ± 7.89)μmol/L; ( 19.52 ± 5.67 ) ng/L, ( 20. 74 ± 6. 13 ) ng/L vs. ( 51.26 ± 11.66 ) ng/L, ( 3.21 ± 1.36) mg/L,(3.24 ± 2.51 ) mg/L vs. ( 8.86 ± 1.32 ) mg/L respectively, all P ＜ 0. 01 ]. Conclusions The levels of serum Hcy, IL-6, hs-CRP are significant biomarkers to evaluate the severity and prognosis of acute stroke.
